Insulin to Account for 32% of the Indian Diabetes Medication Market by 2018

Document Sample
Insulin to Account for 32% of the Indian Diabetes Medication Market by 2018 Powered By Docstoc
					Insulin to Account for 32% of the Indian Diabetes Medication Market
by 2018


A new report expects the Indian insulin market to grow at a CAGR of 19% during 2013-2018.


IMARC Group, one of the world’s leading research and advisory firms, expects the total market
for insulin in India to grow at a CAGR of 19% during 2013-2018. Findings from its latest report
entitled “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-
diabetics, Insulin and Diagnostics” suggests that by 2018, insulin is expected to account for
32% of the entire diabetes medication market in India.


According to the report, the market for both oral anti-diabetics and insulin are experiencing
robust growth. The report cites increasing sedentary lifestyles, lack of physical activity, obesity,
stress and consumption of diets rich in fat, sugar and calories as the catalysts in driving the
prevalence of diabetes in India. According to an analyst at IMARC Group, “India’s rapid
economic growth in the last few decades has led to a rapid urbanization in the country. Between
1991 and 2011, the proportion of people living in urban India rose from 26% to 31%; a trend that
is predicted to increase at a faster pace in the coming years. Increased prosperity has brought
an increase in sedentary lifestyles and western diets. As a result, the prevalence of diabetes in
the urban regions has been much faster compared to the rural regions”.


IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence,
Oral Anti-diabetics, Insulin and Diagnostics” provides an analytical and statistical insight into
the Indian diabetes market. The report provides both current and future trends in the
prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report
has segmented the Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and
Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical
and future market sales, performance of key classes and the performance of top players.




To buy the complete report or to get a free sample, please contact:



IMARC Group Asia
Email: apac@imarcgroup.com

Phone: +91-120-415-5099



IMARC Group North America

Email: america@imarcgroup.com

Phone: +1-631-791-1145



IMARC Group Europe, Middle East & Africa

Email:ema@imarcgroup.com

Phone: +44-702-409-7331



To know more please visit: http://www.imarcgroup.com/india-diabetes/

				
DOCUMENT INFO
Description: A new report expects the Indian insulin market to grow at a CAGR of 19% during 2013-2018.